RYTALO
RYTALO
Industry:
Advertising Business Development Digital Marketing Information Technology SEO
Founded:
2014-01-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.rytalo.com
Total Employee:
11+
Status:
Active
Contact:
1-647-289-9665
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API LetsEncrypt WordPress Content Delivery Network Apache Wordpress Plugins Nginx
Similar Organizations
DeazSolution
DeazSolution is a digital marketing and web development company.
Legendary Marketer
Legendary Marketer is a digital marketing and marketplace company.
Redwoods Digital
Redwoods Digital is a 360 Marketing & Tech Product Development Company
Official Site Inspections
http://www.rytalo.com
- Host name: websites.rytalo.com
- IP address: 159.203.19.2
- Location: Toronto Canada
- Latitude: 43.6547
- Longitude: -79.3623
- Timezone: America/Toronto
- Postal: M5A
More informations about "Rytalo"
Instructions for creating a list of patients who may be appropriate …
RYTELO (imetelstat) is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic ... which are solely the responsibility of the organization. The process outlined …See details»
Geron finally brings a drug to market as FDA clears …
6 days ago The US regulator has cleared Rytelo (imetelstat) for adults with lower-risk MDS who have transfusion-dependent anaemia and have stopped responding to or cannot be treated with erythropoiesis ...See details»
INDICATIONS AND USAGE DOSAGE AND ADMINISTRATION …
• Calculate the dose of RYTELO needed based on the patient’s body weight (kg). • Determine the number of RYTELO vials needed to achieve the required dose (total mg) per Table 4. More …See details»
Rytelo | European Medicines Agency (EMA)
Rytelo is given by infusion (drip) into a vein, usually over a period of around two hours; it is given once every four weeks. The recommended dose depends on the patient’s weight and can be …See details»
FDA approves imetelstat for low- to intermediate-1 risk …
On June 6, 2024, the Food and Drug Administration approved imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk ...See details»
Imetelstat - Wikipedia
Imetelstat, sold under the brand name Rytelo, is an anti-cancer medication used for the treatment of myelodysplastic syndromes with transfusion-dependent anemia. [1] Imetelstat is an …See details»
Rytelo: Uses, Dosage, Side Effects, Warnings - Drugs.com
Jul 16, 2024 Rytelo is administered as an intravenous infusion into your vein over 2 hours by a healthcare provider. It is usually given every 4 weeks. Before treatment, your healthcare provider will administer the following pretreatment …See details»
After 33 years, Geron’s first approval marks …
Jun 26, 2024 A winding path. Rytelo’s long journey to approval began when two scientists, Elizabeth Blackburn and Carol Greider, discovered telomerase in 1984.Eventually, that …See details»
RYTELO™ (imetelstat) HCP Website | RYTELOHCP
RYTELO™ (imetelstat) is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more …See details»
FDA-Approved Rytelo a ‘Game Changer’ for …
Jun 17, 2024 The approval by the Food and Drug Administration of Rytelo (imetelstat) for the treatment of some patients with myelodysplastic syndromes (MDS) could mark a significant …See details»
BILLING AND CODING - rytelohcp.com
IMPORTANT: J0870: Permanent J-code for RYTELO effective for dates of service on or after NOTE January 1, 2025 Note ☐ Be sure to bill according to the amount of RYTELO …See details»
Rytalo - Crunchbase Company Profile & Funding
Experience the new Crunchbase, powered by AI . Organization. RytaloSee details»
Logo Royalty Pharma
5 Rytelo –uniquely positioned to address unmet need in LR-MDS LR-MDS: lower-risk myelodysplastic syndromes; FDA: Food and Drug Administration 1. Payments to Royalty …See details»
FDA signs off on Geron's long-awaited bone cancer drug Rytelo
Jun 7, 2024 Geron has set the wholesale acquisition cost for a single-dose vial of 47 mg of Rytelo at $2,471, while a single-dose vial of an 188 mg dose goes for $9,884. Dosages are …See details»
Rytelo™ - Vivo Infusion Therapy
Mar 15, 2025 Rytelo™ (imetelstat) is a first-in-class telomerase inhibitor approved for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) …See details»
New Treatment Approved for Certain Patients Living With …
Jun 7, 2024 The U.S. Food and Drug Administration has approved imetelstat (known commercially as RYTELO) to treat some patients with the rare blood cancer, myelodysplastic …See details»
Reconstitution and Administration Guide - rytelohcp.com
Prior to initiation of RYTELO, weekly for the first two cycles, prior to each cycle thereafter, and as clinically indicated. Administer platelet transfusions as appropriate. Delay the next cycle and …See details»
ICER says Geron's just-approved Rytelo is too pricey
1 day ago Moreover, it also says that Rytelo would only meet its cost-effectiveness thresholds if its price was reduced to $94,800-$113,000 per year. Despite its name, lower-risk MDS is a …See details»
Geron Announces European Commission Approval of RYTELO® …
Mar 12, 2025 The marketing authorization of RYTELO approved by the EC is supported by data from the IMerge Phase 3 clinical trial, which demonstrated the significant clinical benefit of …See details»
Rytelo: Dosage, side effects, uses, interactions, cost, and more
Feb 20, 2025 Rytelo (imetelstat) is a prescription intravenous infusion for a certain group of blood cancers. Learn about dosage, side effects, and more.See details»